Christian Hoelscher on Honolulu: Neuroregeneration Taps Glia, Neurotrophins

COMMENT The effects of BDNF on neuronal protection and synapse preservation are most impressive, similar to those shown by NGF. As they do not cross the blood-brain barrier (BBB), new methods are tested, such as the stem cell injection or genetic vector transfer

GluR 1 /GluA 1 (160E5)

ANTIBODY monoclonal 160E5 manufacturer Cat# 182 011<br />Reference: <br /><a href="/papers/altered-histone-acetylation-associated-age-dependent-memory-impairment-mice" target="_new">Peleg, 2010</a> Immunogen = synthetic

Alzheimer's Association International Conference on Alzheimer's Disease 2010

CONFERENCE COVERAGE SERIES Honolulu: FDA Approval in Sight for 18F Amyloid Tracer Florbetapir? Honolulu: Tomm40 Reported to Track With Brain Atrophy, Cognition Honolulu: TrialMatch Launched as AD Is Becoming “Desktop” Disease Honolulu: The Missing Link? Tau Mediates Aβ Toxicity at

MAP2 (198A5)

ANTIBODY monoclonal 198A5 manufacturer Cat# 188 011<br />Reference: <br /><a href="/papers/altered-histone-acetylation-associated-age-dependent-memory-impairment-mice" target="_new">Peleg, 2010</a> immunogen = recombinan

Julie Williams on Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes.

COMMENT Last year we published a GWAS of AD, and, together with an independent study, identified CLU, PICALM, and CR1 as susceptibility loci for Alzheimer disease (see Harold et al., 2009 and Lambert et al., 2009). These associations are replicated in the present

Annie Prado Jean

Limoges, France

Anti-Aβ Oligomer Headed for Phase 3 Clinical Trial

RESEARCH NEWS 2010-08-13 Research News Top-line data announced this week from a Phase 2 clinical trial of the amyloid-β (Aβ) oligomer blocking drug scyllo-inositol (aka AZD-103, or ELND005) have given Elan Corporation PLC and partner Transition Therapeutics Inc. reason to take th

Research Brief: Lithium for ALS—Another Nail in the Coffin?

RESEARCH NEWS 2010-08-13 Research News Yet again, lithium has failed to live up to its promise in the treatment of amyotrophic lateral sclerosis. In a Neurology article posted online August 11, researchers of the LITALS Study Group report on a multicenter trial in Italy, which wa

Honolulu: Biomarker Profiles That Spell Trouble for ‘Normals’?

CONFERENCE COVERAGE 2010-08-13 Conference Coverage Guided by the latest biomarker and imaging data, scientists have drafted a new set of diagnostic research criteria redefining Alzheimer disease as a condition that develops—and eventually could warrant intervention—decades prior to obv

PAPER Belly A, Bodon G, Blot B, Bouron A, Sadoul R, Goldberg Y

CHMP2B mutants linked to frontotemporal dementia impair maturation of dendritic spines.

J Cell Sci. 2010 Sep 1;123(Pt 17):2943-54. PubMed: 20699355

PAPER Crippa V, Carra S, Rusmini P, Sau D, Bolzoni E, Bendotti C, De Biasi S, Poletti A

A role of small heat shock protein B8 (HspB8) in the autophagic removal of misfolded proteins responsible for neurodegenerative diseases.

Autophagy. 2010 Oct;6(7):958-60. PubMed: 20699640

PAPER Stefani M

Protein aggregation diseases: toxicity of soluble prefibrillar aggregates and their clinical significance.

Methods Mol Biol. 2010;648:25-41. PubMed: 20700703

PAPER Bucciantini M, Cecchi C

Biological membranes as protein aggregation matrices and targets of amyloid toxicity.

Methods Mol Biol. 2010;648:231-43. PubMed: 20700716

PAPER Zhou JY, Afjehi-Sadat L, Asress S, Duong DM, Cudkowicz M, Glass JD, Peng J

Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach.

J Proteome Res. 2010 Oct 1;9(10):5133-41. PubMed: 20698585

PAPER Andrasfalvy BK, Zemelman BV, Tang J, Vaziri A

Two-photon single-cell optogenetic control of neuronal activity by sculpted light.

Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11981-6. PubMed: 20543137